Introduction
Breast cancer is the leading cause of cancer death among women worldwide (1) .
Among the subtypes of breast cancer, triple-negative disease is associated with a particularly poor prognosis and limited therapeutic options (2) . During breast cancer treatment therapy resistance and metastatic dissemination are the main problems that have to be faced (1) . Of note, breast cancer stem cells have been suggested to be responsible for both therapy resistance and metastatic dissemination (3, 4) . Until now, these resistant cancer stem cell populations have only been poorly characterized and targeted therapeutics have yet to be identified.
It has been shown that alterations of epigenetic regulators such as the KDM4 family members control tumor cell proliferation particularly in aggressive breast cancers (5) and dysregulation of KDM4 demethylases has been documented in a variety of cancers including breast cancer (6) . The KDM4 subfamily is comprised of KDM4A, B, C, and D and belongs to the Jumonji C (JmjC) domain-containing family of histone demethylases (7) . KDM4 demethylases catalyze removal of the repressive H3K9me3 mark and that of H3K36me3, a mark linked to transcriptional elongation (8) thereby regulating a range of crucial pathways. These findings highlight KDM4 demethylases as potential therapeutic targets for breast cancer treatment.
Consequently, we set out to test potent and selective drug-like KDM4 inhibitors. In order to validate inhibitors on cancer stem cells (CSCs) from triple-negative breast cancer, we established an efficient 3 dimensional (3D) cultivation method allowing for growth of CSCs from patient tumor tissue without prior fluorescence-activated cell sorting (FACS) or murine xenografts to enrich for CSCs. We used defined conditions including a serum-free culture medium, a rho kinase inhibitor, Matrigel, Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472. CAN-17-1754 and a low oxygen environment to isolate and enrich for BCSCs from individual patient tumors after neoadjuvant chemotherapy.
Materials and Methods

Tissue specimens
All patients were operated at the Department of Obstetrics and Gynecology at the University Medical Centre Freiburg. Tumor tissue specimens for BCSC isolation and paraffin embedding were obtained from pathologists of the tumor bank of the Comprehensive Cancer Centre Freiburg. All experiments were performed in accordance with the Declaration of Helsinki. We confirm that all experimental protocols were approved by the institutional review board (IRB) in the Ethics vote 307/13 (independent Ethics Committee University of Freiburg). Written informed consent was obtained from each patient.
BCSC isolation method
All primary breast cancer tumors were collected from individuals who had received chemotherapy and were classified as triple-negative. Primary breast cancer stem cell (BCSC) lines were isolated by mechanical dissociation of the tumor material followed by enzymatic digestion in 5 ml DPBS (Gibco) supplemented with 6 units DNAse I (Machery-Nagel) and 1 mg liberase (Roche) for 1 h at 37 °C. Afterwards, the digestion medium was diluted with 10 ml DPBS and filtered through a cell strainer (40 µm, BD). Following centrifugation at 200 g for 5 min, the supernatant was discarded and the cell pellet was washed with MEBM (Gibco). Subsequently, if red blood cells were visible in the pellet, 2 ml ACK Lysis-buffer (Gibco) was added to the cell pellet. After 1 min incubation at room temperature, the suspension was filled up to 6 ml with MEBM and centrifuged at 200 g for 5 min. The supernatant was 
MSC medium
The mammary stem cell (MSC) medium is composed of mammary epithelial basal medium (Gibco, 31331-028), supplemented with 1 x B27 (Gibco, 17504-044), 1 x amphotericin B (Sigma-Aldrich, A2942), and 1 x penicillin-streptomycin (Gibco, 15140122). Furthermore, epidermal growth factor (20 ng/ml, PeproTech, AF-100-15), heparin (4 µg/ml, Sigma-Aldrich, H3149), fibroblast growth factor (20 ng/ml, PeproTech, AF-100-18B), gentamicin (35 µg/ml, Gibco, 15750-045), and rho kinase inhibitor (500 nM, Calbiochem, 555552) were added.
Cell culture
Research. BCSCs were cultured as spheres in a 3D environment as described above. One ml medium was added after 2 days. Cells were split once a week using Dispase (Corning) to solve residual Matrigel and Accutase for sphere dissociation. To expand BCSCs in a 2D environment, 4 x 10 5 cells were seeded in 2 ml MSC medium containing 2 % Matrigel (ice-cold) in a 10 cm culture dish. After solidification of the Matrigel at 37
°C for 30 min, the dish was topped up with 8 ml of MSC medium. Cells were grown under low oxygen conditions as described above. Medium was changed after 3 days.
Cells were split once a week.
Anchorage-independent cancer stem cell sphere assay in methylcellulose 
10
4 single BCSC1 and BCSC2 spheres were seeded and treated as described above.
After 7 days, BCSC1 and BCSC2 cells were split and counted as described above.
From these, 1 x 10 3 single BCSC1 and BCSC2 cells were seeded in triplicates as described above to assess secondary sphere formation in the absence of QC6352, QC6688 or paclitaxel. After 7 days, spheres over 50 µm diameter were counted for QC6352-and QC6688-treated and control cells and spheres over 20 µm diameter were counted for paclitaxel-treated and control cells.
Cell proliferation assay
High titer lentiviral stock (CMV-NLS-mCherry) was obtained from the Sanford
Burnham Prebys Medical Discovery Institute. Lentiviral particles were added at an MOI of 5 to BCSC1 and BCSC2 in MSC medium. Cells were cultured as described. 
Adenoviral knockdown of KDM4 isoforms
High titer adenoviral stocks (shRNA Ctrl (Ad-GFP-U6-scrambled-shRNA; #1122N), shRNA KDM4A (Ad-GFP-U6-h-KDM4A-shRNA; #shADV-212841), shRNA 
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed essentially as previously described (10 3' and 5'-ttctgtctgcacacttggca-3'. Libraries were prepared from immunoprecipitated DNA according to standard methods. ChIP-seq libraries were sequenced using a HiSeq 2000 (Illumina) and mapped to the hg19 reference genome using bowtie 2 (11) . Data were further analyzed with the peak finding algorithm MACS 1.42 (12) using input as control. Normalization to spike-in chromatin was performed according to Ref (13) . All peaks with FDR greater than 0.5 % were excluded from further analysis. The uniquely mapped reads were used to generate the genome-wide intensity profiles, which were visualized using the IGV genome browser (14) . HOMER (15) was used to annotate peaks, to calculate overlaps between different peak files, and for motif searches. The genomic features (promoter, exon, intron, 3'UTR, and intergenic regions) were defined and calculated using Refseq and HOMER. Data are deposited under GSE95294.
Orthotopic breast cancer xenografts
All animal studies and experiments were performed in accordance with German Animal Welfare regulations and in accordance with an Institutional Animal Care and Use Committee (IACUC) as described in the animal protocol G13/114. NOD/SCID females (4-5 weeks old) were anesthetized using an isoflurane inhalator. A small sagittal incision (no longer than 1.0 cm) on the shaved and sterilized abdomen allowed access to the mammary gland #4 on both sides. Indicated numbers of BCSCs were mixed with 1 x 10 6 irradiated fibroblasts (newborn human foreskin fibroblasts incisions were sealed by suturing with a 5/0 thread (Ethicon, Z995). Animals were monitored twice weekly for weight and tumor growth, which was determined by caliper measurement. Tumor volumes were calculated using the formula 4/3 x π x r 3 .
Ultrasonic 3D tumor model
Ultrasound measurements of xenograft tumors in NOD/SCID mice were performed using a small animal high resolution ultrasound system (Vevo3100) and transducer (MX550D) with 40 MHz (VisualSonics). For 3D tumor modeling, the transducer was moved along the tumor automatically with a step size of 0.076 mm. Tumors were visualized with Vevo LAB (Version 1.7.1) at start and end of treatment.
In vivo treatment with QC6352
Immediately before treatment, QC6352 was dissolved in 50 % polyethylene glycol 
Microarray analysis
Total RNA was isolated from patient tumor material, xenografts, and cells using the 
Flow cytometry
To analyze the expression of established CSC markers, cells were detached and 
Western blot analysis
Experiments were performed as previously described (10) 
RNA preparation and analysis
Cells were cultured in the presence of vehicle or 5 x 10 -8 M QC6352. RNA was isolated as previously described (19) . Quantitative RT-PCR was performed using the Abgene SYBR Green PCR kit (Invitrogen) according to the supplier's protocol.
HPRT was used for normalization. Primer sequences for HPRT were described previously (20) . facility of the DKFZ. Reads were aligned to the hg19 build of the human genome using TopHat version 2 (21) . The aligned reads were counted with the homer software (analyzeRNA) and DEG's were identified using EdgeR (22). Data are deposited under GSE95294.
Pharmacokinetic analyses
An intravenous dosing solution was made by dissolving QC6352 into phosphate buffered saline. The pH was adjusted to 9 by dropwise addition of 1 N NaOH. An oral dosing suspension was made by dissolving QC6352 into 0.5 % methylcellulose. The intravenous and oral dosing solutions were administered at 5 mg/kg and 10 mg/kg, respectively, to female CD-1 mice. Pharmacokinetic parameters were calculated as the average of groups consisting of three animal.
Statistical analyses
Data are represented as mean and standard deviation (SD) or standard error of the mean (SEM) as indicated. Significance was calculated by a two-tailed Student's t test or one-way ANOVA as indicated with GraphPad Prism Version 6. P-values below 0.05, 0.01, and 0.001 are indicated in figures as *, **, and ***, respectively.
Determination of the QC6352 IC 50
The ability of QC6352 to inhibit the activity of different KDM family members was 
Results
Breast cancer stem cell xenografts recapitulate original tumors of patients
As shown in Table 1 , we established four breast cancer stem cell lines (BCSC1-4), which originate from four independent breast tumor samples lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) proteins. BCSCs could be cultivated in a 2D and 3D environment and grew as epithelial clusters and spheres, respectively ( Figure 1A and Supplementary Fig. S1A ). In vitro clonogenic assays such as sphere formation assays have been developed to study proliferation, self-renewal, and differentiation of cell populations at the single-cell level (23) . Thus, to verify their stem cell potential BCSC1 and BCSC2 were challenged in an anchorage-independent growth assay.
BCSC1 and BCSC2 demonstrated a sphere-forming capacity of 10.8 % and 16.2 %, respectively, providing evidence for the potential of BCSC1 and BCSC2 to self-renew ( Figure 1B and Supplementary Fig. S1B ). CSCs from breast cancer have been described to express specific surface markers such as CD49f, EpCAM, and CD44 while lacking expression of CD24 (24, 25 Figure   1C , 1D, Supplementary Fig. S1C , and S1D). The flow cytometric analysis clearly
showed that BCSC1 and BCSC2 harbor a stem cell population. To further corroborate the stem cell potential of the BCSCs we performed limiting dilution orthotopic xenografts in immunocompromised NOD/SCID mice, the current gold standard assay for self-renewing CSCs. As few as 1x10 3 BCSC1 and BCSC2 were able to form tumors demonstrating that both cell lines contain tumorigenic CSCs ( Figure 1E , 1F, and Supplementary Fig. S1E ). In summary, we used three independent methods namely sphere formation, flow cytometry analysis, and xenografts to demonstrate stemness, self-renewal capacity, and tumorigenicity of BCSC1 and BCSC2.
To further address the ability of these cells to regenerate the original patient tumor in a xenograft tumor model we analyzed tumors derived from BCSC1 and tumors ( Figure 1G and Supplementary Fig. S1F ). Matching the parental tumor, the BCSC xenografts were devoid of ER, PR and HER2 protein expression (Table 1 , Figure 1H , and Supplementary Fig. S1G ). Unsupervised hierarchical clustering analysis of RNA microarray data showed that the BCSC tumor xenografts share a close expression profile with the parental patient tumors indicating preservation of the respective molecular tumor subtype ( Figure 1I ). BCSC lines clustered within the corresponding host tumor and xenograft subtype depicting a close correlation between the three entities ( Figure 1I ). Taken together, our data demonstrate that BCSCs can be isolated from triple-negative breast cancer patient tissue using optimized culture conditions and faithfully recapitulate the patient tumor in xenografts.
KDM4A controls proliferation and xenograft tumor growth of BCSC1
To evaluate the expression levels of the KDM4 family members in BCSC1 and BCSC2 we performed Western blot analysis. As shown in Figure 2A , we detected robust expression of KDM4A in both BCSC1 and BCSC2. In contrast, expression levels of KDM4B, C and D were more heterogeneous (Figure 2A) . To see whether KDM4s control proliferation of BCSC1 we performed adenoviral shRNA-mediated knockdown of KDM4A, B, C, and D in BCSC1 and monitored proliferation in realtime. As shown in Figure 2B , depletion of KDM4A impaired proliferation of BCSC1 cells. In contrast, knockdown of KDM4B, C or D did not influence proliferation of BCSC1 (Supplemental Fig. S2A-S2E ).
Next, we wondered whether knockdown of KDM4A affects growth of BCSC1 xenografts. Therefore, BCSC1 were infected with adenovirus encoding either shRNA control (shRNA Ctrl) or shRNA against KDM4A (shRNA KDM4A) and implanted into the fat pads of immunocompromised NOD/SCID mice. Importantly, upon Fig. S2F-S2H) . Together, our data demonstrate that the histone demethylase KDM4A controls proliferation and xenograft tumor growth of BCSC1. Furthermore, our bioinformatic analyses indicate that relapse-free survival (RFS) over time decreases for patients with TNBC that express high levels of KDM4A in comparison to patients with TNBC that express low levels of KDM4A ( Supplementary Fig. S2I ). These findings indicate that targeting KDM4 might be a therapeutic option to limit expansion of BCSC populations.
QC6352 is a potent KDM4 inhibitor that blocks proliferation of BCSCs
Based on our observations that KDM4A controls proliferation and xenograft tumor growth of BCSC1 we decided to test whether the drug-like KDM4 inhibitor QC6352
(also called compound 6)(26) might qualify for the treatment of BCSC-originating tumors ( Figure 3A) . As a first step, prior to any investigation of either biological function or underpinning mechanism of action, we assessed the selectivity profile of the inhibitor. QC6352 was evaluated against the KDM4 subfamily and other JmjC domain-containing histone demethylases such as KDM2A, 2B, 5B, 6A, and 6B. Figure 3B ). QC6352 showed 100-to 300-fold selectivity over KDM2 and KDM6 demethylases and only weak inhibition of KDM5B ( Figure 3B) . Finally, QC6352's favorable pharmacokinetic properties warranted further in vivo investigation ( Figure 3C ). In summary, QC6352 presented as an orally available, potent, and selective KDM4 inhibitor. When investigating the in vitro efficacy of QC6352 in BCSCs we observed that concentrations as low as 10 nM inhibited BCSC1 and BCSC2 cell proliferation ( Figure 3D , 3E, and Supplementary Fig. S3A , and S3B). To characterize and define the effect of QC6352 on stem cell potential (self-renewal and differentiation) we tested whether QC6352 treatment might interfere with the sphere-forming capacity of both BCSCs. Consequently, BCSCs were plated as single cells to ensure clonality and inspected for one week. In a concentration-dependent manner QC6352 dramatically reduced the anchorage-independent sphere-forming capacity of BCSC1 and BCSC2
( Figure 3F and Supplementary Fig. S3C ). We then isolated single cells from one week QC6352-treated spheres and evaluated for anchorage-independent sphere-formation in a secondary assay in the absence of QC6352. Of note, the secondary sphereforming capacity was blocked even in the absence of inhibitor ( Figure 3G and Supplementary Fig. S3D ). In contrast, the differentiation-inducing LSD1 inhibitor QC6688 (27) neither affected primary nor secondary sphere formation (Supplementary Fig. S3E and S3F ). In addition, chemotherapeutics such as the taxane paclitaxel impaired proliferation of BCSC1 in primary sphere formation but did not interfere with stem cell potential and thus allowed secondary sphere formation ( Supplementary Fig. S3G ). Taken together, our data demonstrate that QC6352 blocks proliferation and self-renewal of BCSCs.
QC6352 targets BCSCs through EGFR regulation
To unravel the molecular mechanism underlying the action of the inhibitor we performed transcriptome analyses to identify genes that were differentially regulated upon QC6352 treatment. BCSC1 were cultivated in the presence or absence of QC6352 and subjected to RNA-seq. Our analysis identified a total of 580 Fig. S4A ). Only 3221 (6.9%) KDM4A locations were observed in BCSC1 treated with shRNA against KDM4A, thus confirming specificity of the KDM4A antibody (Supplementary Fig. S4B ). This finding prompted us to intersect the KDM4A cistrome with the QC6352 transcriptome. Among the 580 differentially regulated genes, KDM4A was present at the promoter of 258 genes (44%) ( Figure 4C ). Pathway analysis for these 258 genes revealed that 30 of these genes, including EGFR, belong to the 'EGF receptor signaling pathway' ( Figure 4D) . We verified by qRT-PCR analysis that treatment with QC6352 reduced the expression levels of genes such as versican (VCAN), proline rich 5 (PRR5), activating transcription factor 4 (ATF4), early growth response 1 (EGR1), follistatin (FST), and importantly EGFR ( Figure 4E ). EGFR is an emerging therapeutic target that is associated with poor clinical outcome of triplenegative breast cancer (28) . To unravel the importance of EGFR signaling in growth of BCSCs we treated BCSC1 and BCSC2 with erlotinib, a specific EGFR inhibitor.
Of note, treatment with erlotinib blocked proliferation of both BCSC1 and BCSC2
( Supplementary Fig. S4C-S4F) . Furthermore, stem cell potential measured by anchorage-independent sphere-forming capacity of both BCSC1 and BCSC2 was dramatically reduced upon treatment with erlotinib ( Supplementary Fig. S4G and   S4H ). Together, these data demonstrate that EGFR, at least in part, controls growth and stem cell potential of BCSCs. As shown by Western blot analysis the protein 
levels of EGFR were reduced in both BCSC1 and BCSC2 upon treatment with QC6352 ( Figure 4F and Supplementary Fig. S4I ). Since EGFR is a direct KDM4A target, we tested whether knockdown of KDM4A affects EGFR protein levels. As depicted in Figure 4G and Supplementary Fig. S4J , shRNA-mediated knockdown of KDM4A led to reduced levels of EGFR in both BCSC1 and BCSC2. Of note, knockdown of KDM4B, C, or D in BCSC1 did not affect the levels of EGFR ( Supplementary Fig. S4K-S4M) . Taken together, the data show that EGFR expression in BCSCs is blocked by QC6352 via inhibition of KDM4A.
Since KDM4A is a demethylase that erases the repressive H3K9me3 mark, we hypothesized that an increase in H3K9me3 should be observed upon inactivation of KDM4A by QC6352. To this end, we performed genome-wide ChIP-seq with H3K9me3 antibody in BCSC1 cells that were treated with either vehicle or QC6352.
To allow for normalization of H3K9me3 ChIP-seq tags, we added spike-in chromatin during the ChIP procedure (13) . The analysis shown in Supplementary Figure S5A identified 141,722 high confidence H3K9me3 peaks in vehicle-treated cells and 144,266 peaks in cells treated with QC6352. Importantly, we observed a global increase of the H3K9me3 reads over the KDM4A peaks ( Figure 5A ). Similarly, on the EGFR promoter we also observed increased levels of the repressive H3K9me3 mark over the KDM4A peak subsequent to inactivation by QC6352 ( Figure 5B ). To demonstrate that the increase of H3K9me3 levels at the EGFR promoter upon treatment with QC6352 is due to inhibition of KDM4A, we infected BCSC1 cells with adenovirus encoding either shRNA control (shRNA Ctrl) or shRNA against KDM4A (shRNA KDM4A) and performed ChIP assays. ChIP-qPCR analyses indicate that in BCSC1 infected with shRNA KDM4A the levels of H3K9me3 at the EGFR promoter increase concomitantly to a decrease in KDM4A when compared to Figure 5C ). In summary, these results demonstrate that treatment of BCSCs with QC6352 targets EGFR via inhibition of the KDM4A demethylase activity.
QC6352 inhibits BCSC-derived xenograft tumor growth
Next, we wondered whether QC6352 might affect growth of BCSC1 and BCSC2 Author Manuscript Published OnlineFirst on September 7, 2017; DOI: 10.1158/0008-5472. CAN-17-1754 population is marked by CD24 low /CD44 high cells (24) . In addition, several other surface molecules such as CD61, CD49f and EpCAM identifying BCSCs were proposed (29, 30) . Importantly, due to a lack of appropriate culture conditions BCSCs cannot be cultivated continuously in vitro in a stem cell state (31, 32) . To address this issue and to stabilize the CSC phenotype we used a 3D Matrix and applied a Rho
Kinase inhibitor in a low oxygen environment. Thus, our culture conditions allowed In recent years diverse KDM4 inhibitors have been identified, which act either as α-ketoglutarate mimics, a cofactor essential for the enzymatic function of KDM4s, or as inhibitors of the catalytic site (8) . These molecules showed inhibitory effects on KDM4s in vitro and in cell culture models (8) . However, these KDM4 inhibitors did not qualify as therapeutic agents. In contrast, QC6352 is a drug-like KDM4 inhibitor that is potent, selective, orally available, and presents favorable pharmacokinetic properties.
In summary, we established an advanced culture method that allows isolation and growth of BCSC lines isolated from individual patient tumors after neoadjuvant chemotherapy. We demonstrate that BCSC xenografts faithfully recapitulate parental patient tumors and that BCSCs, BCSC xenografts and the parental tumors share a highly similar transcriptome and phenotype profile. Therefore, our models are ideal tools for the identification and validation of novel therapeutics. In line with this idea, we identified the histone demethylase KDM4A as a therapeutic target for BCSCoriginating tumors. Consequently, we showed that the orally available, potent, and selective KDM4 inhibitor QC6352 abrogates expression of target genes via inhibition of the KDM4A demethylase activity thereby blocking proliferation, sphere-forming capacity in vitro and xenograft tumor growth of BCSCs in vivo. Thus, modulation of KDM4 activity is a promising therapeutic strategy for the treatment of triple-negative breast cancer.
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